جستجوی استاد راهنمای دانشگاهی

Shijie Caoمشاهده پروفایل

استادیار

• Biotechnology
• Chronic Disease
• Drug Formulation
• +۷ مورد دیگر

Dr. Shijie Cao serves as an Assistant Professor in the Department of Pharmaceutics at the University of Washington School of Pharmacy, where he leads the Cao Lab focused on innovative drug delivery approaches for immunological disorders. His research bridges pharmaceutical sciences with immunology to develop novel therapeutic strategies targeting the microbiome and immune system. Dr. Cao earned his Bachelor of Science in Pharmacy from Fudan University in Shanghai, China in 2013, followed by a PhD in Bioengineering from the University of Washington in 2018. He completed postdoctoral training in Molecular Engineering at the University of Chicago from 2019-2023 before joining the UW faculty in June 2023. His research program centers on mucosal immunoengineering and microbiome pharmaceutics , with the goal of developing translatable tools to prevent and treat immunological disorders including allergies, inflammation, autoimmune diseases, and infectious diseases. The lab specifically focuses on developing therapeutics that modulate the immune system by targeting the microbiome and its associated metabolites. By leveraging advanced drug delivery tools and microbiome modulation strategies, Dr. Cao's team aims to unravel the complex interplay between the microbiome and various organ systems to improve human health. Analysis of Dr. Cao's recent publications reveals a strong trajectory in developing microbiome-targeted therapies, particularly using butyrate and other microbial metabolites for autoimmune conditions and food allergies. His work demonstrates increasing sophistication in delivery systems, with recent publications focusing on glycosylation-modified antigens for tolerance induction, serine-conjugated butyrate prodrugs with high oral bioavailability, and injectable butyrate-prodrug micelles for long-acting immune modulation. The research spans applications from autoimmune arthritis and neuroinflammation to peanut allergy treatment and chronic wound healing. Dr. Cao actively collaborates with prominent researchers including Jeffrey A. Hubbell and maintains strong connections with his previous mentors at the University of Chicago. His work frequently appears in high-impact journals including Nature Biomedical Engineering, Cell Reports Medicine, and Biomaterials, reflecting the significance and innovation of his contributions to pharmaceutical sciences. The Cao Lab is currently accepting graduate students and maintains active research programs in two primary areas: developing tolerance-inducing vaccines for food allergies and autoimmune conditions, and creating microbiome-targeted delivery systems for inflammatory and autoimmune diseases. The lab employs interdisciplinary approaches combining nanotechnology, immunology, and microbiome science to address unmet medical needs in immune-mediated disorders.

Cole A. DeForestمشاهده پروفایل

دانشیار

• Biomaterials
• Tissue Engineering
• Stem Cell Biology
• +۷ مورد دیگر

Cole A. DeForest is a Weyerhaeuser Endowed Professor and Associate Professor in the Department of Chemical Engineering at the University of Washington, where he also serves as Associate Chair for Graduate Studies. Additionally, he holds appointments as Associate Professor in Bioengineering and Adjunct Associate Professor in Chemistry, and is the Director of Education at the Molecular Engineering & Sciences Institute and a Core Faculty member at the Institute for Stem Cell & Regenerative Medicine. Dr. DeForest earned his Ph.D. in Chemical and Biological Engineering from the University of Colorado, Boulder in 2011 and completed postdoctoral training at Caltech before joining the UW faculty in 2014. His research focuses on developing user-programmable hydrogels with tunable biochemical and biophysical properties, utilizing cytocompatible bioorthogonal chemistries, particularly those initiated with light. His work spans several key areas including User-Programmable Biomaterials for Directing Dynamic Stem Cell Fate, Biomolecular and Tissue Engineering, Controlled Delivery of Therapeutics to Treat Disease, and Tool Development for Enhanced Proteomic Studies. His publication record demonstrates consistent high-impact contributions to biomaterials science, with numerous papers in Nature family journals, JACS, and Advanced Materials. His research approach integrates principles of rational design with fundamental concepts from material science, synthetic chemistry, and stem cell biology to create next-generation materials addressing health-related problems. UW College of Engineering Junior Faculty Award (2020) Society for Biomaterials Young Investigator Award (2020) Society for Biomaterials Mid-Career Award (2025) NSF CAREER Award (2017) UW Presidential Distinguished Teaching Award (2016) 35 Under 35 Award, AIChE Bioengineering Category (2017) Dr. DeForest has mentored numerous graduate students, postdocs, and undergraduates, many of whom have received prestigious fellowships including NSF GRFP, NIH F30, and HHMI Gilliam Fellowships. His lab has secured significant funding including collaborative grants from the Institute for Translational Health Sciences, the Institute for Stem Cells & Regenerative Medicine, and the Allen Institute for Brain Science. His educational leadership extends to directing the MolES Education program and teaching courses including Biological Frameworks for Engineers and Biomaterials Seminar.

Carl Johan Sundbergمشاهده پروفایل

استاد

• Molecular Exercise Physiology
• Skeletal Muscle Adaptation
• Mitochondrial Biogenesis
• +۶ مورد دیگر

Carl Johan Sundberg is a Professor at the Karolinska Institutet , affiliated with the Department of Physiology and Pharmacology and the Department of Learning, Informatics, Management and Ethics (2025-2027). He serves as Dean for KI Nord and is a licensed physician. Current research focuses on molecular exercise physiology , including mitochondrial biogenesis , epigenetic regulation , and cardiometabolic disease . Key research areas: Medical Genetics and Genomics , Physiology and Anatomy , Public Health . His work bridges molecular mechanisms in skeletal muscle with clinical applications for diabetes, cancer, and post-stroke rehabilitation. Notable awards include the EMBO Certificate of Commendation and European Commission’s Descartes Communication Prize (2005). Recent publications highlight epigenetic differences between trained/untrained individuals, exercise-induced immune mobilization , and digital health tools for cardiac risk stratification. Grants include funding from the Swedish Research Council and Swedish Heart-Lung Foundation .

• Nanomedicine
• Cancer Therapy
• Metal-Based Chemotherapeutics
• +۳ مورد دیگر

Quim Peña is a postdoctoral researcher at the Department of Experimental Molecular Imaging (RWTH Aachen University). He obtained his PhD in Chemistry from Universitat Autònoma de Barcelona (Spain) and Aix-Marseille Université (France) in 2019, focusing on metal-based chemotherapeutics. Current research focuses on nanomedicine for enhanced drug delivery in cancer therapies Specializes in polymeric micelles and prodrug synthesis Recent work involves RGD-coated microbubbles and ultrasound-mediated delivery Contributed to 89Zr-radiolabeled micelle development for personalized breast cancer treatment His publications (2021-2025) emphasize polymer-drug conjugates , multidrug delivery systems , and theranostic applications . Collaborative projects include collaborations with Twan Lammers, Fabian Kiessling, and Josbert Metselaar. 2025: Hydrophobic ion pairing for micelle drug co-loading 2025: Multidrug micelles for brain tumor treatment 2024: RGD-coated microbubbles for blood-brain barrier delivery 2023: Transformative materials for interfacial drug delivery Scientific recognition includes the 2025 CRS Award for best short talk . His work targets cancer nanomedicine with emphasis on side-effect reduction through advanced delivery systems.

Zalfa Abdel-Malekمشاهده پروفایل

استاد

• Melanocyte Biology
• UV Radiation Response
• Melanoma Prevention
• +۴ مورد دیگر

Zalfa Abdel-Malek is a distinguished Professor in the Department of Environmental Health at the University of Cincinnati College of Medicine, where she has maintained an active research program for over two decades. Her work bridges dermatology, molecular biology, and environmental health, focusing on the mechanisms of skin pigmentation and melanoma development. Her educational background includes a Bachelor's degree in Biology from the American University of Beirut (1974), followed by Master's (1980) and Doctoral degrees (1984) in General Biology from the University of Arizona. She completed postdoctoral training in Dermatology at the University of Cincinnati in 1987, establishing her long-standing relationship with the institution. Dr. Abdel-Malek's research centers on the melanocortin 1 receptor (MC1R) and its role in regulating cutaneous pigmentation and the response to UV radiation. She pioneered work demonstrating that human melanocytes express functional MC1R and that activation of this receptor is critical for the tanning response to UV. Her laboratory discovered that activated MC1R enhances the repair of UV-induced DNA damage, maintaining genomic stability of melanocytes and preventing malignant transformation to melanoma. This work has led to the development of small peptide analogs of α-MSH that could potentially serve as topical agents for melanoma prevention. Analysis of her recent publications reveals a consistent focus on MC1R signaling pathways, DNA repair mechanisms in melanocytes, and the development of melanocortin-based therapeutics for melanoma prevention. Her work increasingly explores the tumor microenvironment, genetic interactions between MC1R variants and other melanoma susceptibility genes, and translational applications of basic research findings. Vitiligo Research Award (1990) from the PanAmerican Society for Pigment Cell Research Aaron B. Lerner Award (2006) from the PanAmerican Society for Pigment Cell Research Myron Gordon Award (2011) from the International Federation for Pigment Cell Societies Dr. Abdel-Malek has secured continuous funding as Principal Investigator on numerous NIH grants, including multiple R01 awards from NIEHS and NCI, as well as funding from the Department of Defense and industry partners. Her current research program includes testing small peptide analogs of α-MSH for melanoma prevention, investigating the impact of MC1R variants on DNA damage response, and exploring novel paradigms in melanoma prevention. She maintains active collaborations with researchers across multiple institutions, particularly with Ana Luisa Kadekaro and other colleagues at the University of Cincinnati.

• Immunology
• Macrophage Biology
• Tumor-associated Macrophages
• +۴ مورد دیگر

Antonio SICA is a Full Professor in the Department of Pharmaceutical Sciences at the University of Eastern Piedmont 'Amedeo Avogadro'. With an extensive research career spanning over three decades, he has published 189 research outputs including articles, reviews, and conference contributions. His ORCID profile (0000-0002-8342-7442) documents his significant contributions to immunology and cancer research. Professor SICA's research primarily focuses on myeloid cells in cancer , particularly tumor-associated macrophages and myeloid-derived suppressor cells . His work explores how these cells contribute to tumor progression, immunosuppression, and response to therapy. Key research areas include immunometabolism, epigenetic regulation of myeloid cells, and the intersection of inflammation with cancer development. Analysis of his recent publications (2021-2024) reveals a strong emphasis on myeloid cell heterogeneity in cancer, immunometabolic pathways , and the role of myeloid cells in age-related diseases . His 2023-2024 work has particularly examined connections between cancer immunology and infectious diseases like COVID-19, demonstrating how immunometabolic interference affects disease outcomes. Advancing the knowledge of human neutrophils displaying polymorphonucler myeloid-derived suppressor cell (PMN-MDSC) functions (2023-2025) BioTher19: Biological bases of immune response in fragile COVID-19 patients Deciphering the molecular and functional heterogeneity of myeloid cells in cancer (2019-2023) Deciphering the epigenetic basis of Myeloid-derived immunosuppression in cancer and therapy (2018-2023) Professor SICA has supervised 5 students throughout his career and maintains active research collaborations across multiple institutions. His work contributes significantly to UN Sustainable Development Goals related to good health and well-being, particularly through advancing cancer immunology and immunotherapy approaches.

Mario Jolicoeurمشاهده پروفایل

استاد

• Biochemical Engineering
• Biomedical Engineering
• Metabolic Engineering
• +۳ مورد دیگر

Mario Jolicoeur is a Full Professor in the Department of Chemical Engineering at Polytechnique Montréal. His research focuses on metabolic engineering, biomedical applications, and bioreactor design. He is affiliated with Spheroid AI Inc. (Co-founder, Scientific Director), Viridios (Collaborating Researcher), and the Institute of Biomedical Engineering (Member). Education: B.Sc.A., M.Sc.A., Ph.D. (Polytechnique Montréal and Paul-Sabatier University, Toulouse), Visiting Engineer (MIT) Jolicoeur develops metabolic engineering tools for cancer therapies and therapeutic agent production, designs mathematical models for cellular metabolism regulation, and creates aseptic culture equipment for diverse cells. His work spans CHO cells , microalgae , and tissue engineering . Recent publications highlight metabolic therapies for ovarian cancer, dynamic modeling of CHO cultures, and lipid production in Chlorella. Trends include cancer metabolism, mitochondrial dynamics, and bioreactor optimization. Supervision: He has mentored 43 graduate students since 1990, including those working on metabolic models, bioreactors, and biotherapies. Notable projects involve methylene blue in cancer treatment, ABE fermentation, and chondrocyte culture systems. Labs & Teams: Collaborates with interdisciplinary groups in biomedical engineering and chemical engineering, utilizing advanced bioreactor platforms and computational models.

Nick Virgilioمشاهده پروفایل

استاد

• Thermodynamics
• Multiphase systems
• Surfaces, interfaces and thin layers
• +۲ مورد دیگر

Nick Virgilio is a Full Professor in the Department of Chemical Engineering at Polytechnique Montréal . His research focuses on soft matter interfaces, polymer blends, and advanced hydrogel systems for biomedical and catalytic applications. Director, Research Laboratory on Surfaces, Interfaces and Soft Matter Member, Research Center for High-Performance Polymer and Composite Systems (CREPEC) Research interests include interfacial phenomena in multiphase systems, self-assembly of soft materials, nanoparticle-hydrogel composites, Pickering emulsions, and polymer microstructure engineering. Scientific awards include the 2010 Canadian Macromolecular Science Thesis Prize and the 2004 Polytechnique Montréal Master's Thesis Award. Recent publications highlight his work in macroporous hydrogels for cancer cell capture, nanoparticle synthesis in soft matrices, and interfacial control of polymer blends. His studies frequently appear in high-impact journals like ACS Applied Materials & Interfaces , Green Chemistry , and Macromolecules . Students under his supervision have explored topics from biofilm mechanics to lunar environment polymer systems across 4 PhD and 6 Master’s theses completed or ongoing.

Steven Leeمشاهده پروفایل

استاد

• Biophysical Chemistry
• Single-Molecule Fluorescence Spectroscopy
• Super-Resolution Imaging
• +۵ مورد دیگر

Professor Steven Lee is a leading figure in biophysical chemistry at the University of Cambridge , where he leads the TheLeeLab in the Yusuf Hamied Department of Chemistry . His research focuses on developing advanced single-molecule fluorescence and multidimensional super-resolution imaging techniques to probe fundamental biological processes at unprecedented spatial precision. Developed novel super-resolution microscopy approaches for 2D/3D visualization of T-cell membrane proteins and histone assembly in fission yeast nuclei Pioneer of 15-20nm resolution imaging strategies through fluorophore kinetics and image reconstruction algorithms Recipient of the 2017 Marlow Prize in Physical Chemistry , Lee's lab produces cutting-edge tools with applications in immunology , neurodegeneration , and cellular biophysics . His team maintains active collaborations with Prof Klenerman (FRS MedSci) and Prof Moerner (Nobel Chemistry 2014). Research Highlights : Molecular origins of immunity through T-cell membrane protein interactions 3D histone dynamics during DNA replication/repair Amyloid aggregate quantification for neurodegenerative disease diagnosis Volumetric imaging innovations via vLUME virtual reality platform

Karin Forsberg Nilssonمشاهده پروفایل

استاد

• Neurooncology
• Neurodegeneration
• Stem Cell Research
• +۸ مورد دیگر

Karin Forsberg Nilsson is a Professor at Uppsala University's Department of Immunology, Genetics and Pathology, where she leads the Neurooncology and Neurodegeneration Research Group. She also serves as Dean of the Faculty of Medicine and holds a Visiting Professor position at the University of Nottingham, UK. Her research focuses on understanding brain tumor biology through genetic analysis and tumor microenvironment studies. Current affiliation: Uppsala University Leadership roles: Professor, Dean, Visiting Professor Research focus: Brain tumor genetics, proteoglycan metabolism, precision medicine Her work investigates how mutations in brain stem cells drive tumor formation and progression, particularly in glioblastoma (GBM) and medulloblastoma (MB). The research team has developed novel methods for analyzing non-coding genome regions in cancer studies and created a large-scale patient-derived glioblastoma stem cell bank (www.hgcc.se). Key findings include the role of heparanase in tumor aggressiveness and the impact of tumor-driven neuroinflammation on treatment resistance.

Dan Peerمشاهده پروفایل

استاد

• Nanomedicine
• RNA Interference (RNAi)
• mRNA Delivery
• +۷ مورد دیگر

Prof. Dan Peer is a full Professor at Tel Aviv University (TAU), serving as Vice President for Research and Development since October 2020. He is the Director of the Laboratory of Precision NanoMedicine and founder of the Center for Translational Medicine and the SPARK TLV program at TAU. His work pioneers systemic, cell-specific delivery of RNA molecules (RNAi, mRNA, circRNA, DNA) and genome editing tools using lipid nanoparticles (LNPs), with transformative applications in cancer (glioblastoma, ovarian cancer, blood cancers) and inflammatory diseases. Research Interests RNA Therapeutics Genome Editing (CRISPR) Cancer Immunotherapy Inflammatory Bowel Diseases Nanoparticle-Based Drug Delivery His lab has produced groundbreaking publications in Nature Nanotechnology , Science , and Nature Biotechnology , and he has authored over 140 patents. Scientific awards include the Kenneth Rainin Foundation Innovator/Breakthrough Awards (2010-2013), AAAS Award, Nanos Award (2017), Litwin IBD Pioneers Award (2020), Roche Distinguished Scientist (2021), and GenScript Distinguished Research Award (2022). He was elected to the US National Academy of Engineering (2023) and the Israel Young Academy (2014). Prof. Peer’s work has led to five spin-off companies and collaborations with BioNTech, Roche, and Merck. His lab combines materials science, molecular biology, and computational drug discovery to translate academic findings into clinical settings.

Ville Paavilainenمشاهده پروفایل

پژوهشگر

• Biochemistry
• Cell Biology
• Molecular Biology
• +۹ مورد دیگر

Ville Paavilainen is a Research Director at the Institute of Biotechnology, University of Helsinki, and supervisor for doctoral programs in Biomedicine and Integrative Life Science. With a postdoctoral background at the University of California, San Francisco (2008–2014), he focuses on Biochemistry , Cell Biology , and Molecular Biology , particularly mechanisms of protein translocation, membrane biology, and structural modeling. His research includes groundbreaking work on Sec61 translocon inhibition for cancer therapy and mitochondrial gene expression noise . Recent publications address lipid scrambling pathways, glioma stem cell targeting, and actin regulation. Active projects span EU-funded drug discovery and NIH collaborations. Key scientific contributions include Elucidating Sec61-client interactions Developing computational models for signal peptide prediction Uncovering mitochondrial-ER communication mechanisms He has supervised PhD theses (e.g., Paul Carlson) and contributed to over 39 research outputs. His work bridges structural biology, computational modeling, and translational pharmacology, with applications in tumor biology and neurodegenerative disease research.

Jasmine Fooمشاهده پروفایل

استاد

• Cancer Evolution
• Mathematical Oncology
• Stochastic Modeling
• +۴ مورد دیگر

Jasmine Foo serves as Associate Head and Distinguished McKnight University Professor at the University of Minnesota-Twin Cities' School of Mathematics, holding the Northrop Professorship and co-directing the Therapy Modeling and Design Center. Her leadership spans academic administration and interdisciplinary research initiatives in mathematical oncology. Foo's research pioneers stochastic evolutionary modeling of cancer dynamics, integrating mathematical theory with clinical data to understand tumor initiation, progression, and treatment resistance. Her group focuses on five interconnected themes: plasticity and epigenetics in tumor evolution; drug resistance optimization; data-driven precision oncology; spatial carcinogenesis; and tumor-microenvironment interactions using organoid models. This work bridges probability theory, systems biology, and clinical oncology to develop novel therapeutic strategies. Analysis of her 15 most recent publications reveals a consistent emphasis on quantitative approaches to cancer evolution, with growing integration of machine learning and high-resolution experimental data. Key trends include modeling phenotypic plasticity in resistance development, optimizing dosing schedules using evolutionary principles, and translating spatial tumor dynamics into clinical applications. Scientific recognition includes: Honorable Mention, Feldman Prize for theoretical contributions to tumor evolution modeling Foo actively mentors graduate students and postdoctoral researchers through the School of Mathematics, with research supported by multiple grants (though specific funding sources aren't detailed). Her group maintains strong collaborations with experimental oncology labs and clinical researchers, facilitating data-driven model validation. She co-leads the Therapy Modeling and Design Center and organizes the UMN MathBio Group Meetings, fostering cross-disciplinary collaboration between mathematicians, biologists, and clinicians in cancer research.

Sandro Santagataمشاهده پروفایل

دانشیار

• Cancer Biology
• Systems Biology
• Pathology
• +۵ مورد دیگر

Sandro Santagata is an Associate Professor in the Department of Systems Biology at Harvard Medical School, where he leads the Santagata Lab. His research focuses on advancing multiplexed tissue imaging technologies in 2D and 3D to study tumor and immune cell interactions within the tumor microenvironment, aiming to identify spatial biomarkers that improve cancer diagnosis and personalized therapies. His work contributes to the NCI Moonshot Human Tumor Atlas Network (HTAN) and collaborations with the Ludwig and Gray Foundations. At Harvard Medical School, he holds dual appointments as Associate Professor of Pathology and Systems Biology. Dr. Santagata trained in the Medical Scientist Training Program (MSTP) at Mount Sinai School of Medicine, completed residency and fellowship in Anatomic Pathology and Neuropathology at Brigham and Women’s Hospital (BWH), and pursued a research fellowship at the Whitehead Institute. He practices diagnostic pathology at BWH and co-leads a research team at the HMS Laboratory of Systems Pharmacology (LSP).

Daniel J. Siegwartمشاهده پروفایل

استاد

• Drug Delivery
• Nanotechnology
• Cancer Research
• +۶ مورد دیگر

Daniel J. Siegwart holds the W. Ray Wallace Distinguished Chair in Molecular Oncology Research and serves as Professor at the University of Texas Southwestern Medical Center. He maintains dual appointments in the Department of Biomedical Engineering and Department of Biochemistry, and is affiliated with the Simmons Comprehensive Cancer Center. Dr. Siegwart directs both the Program in Genetic Drug Engineering and the Drug Delivery Program in Biomedical Engineering, while also serving as Co-Director of the Chemistry and Cancer Program. Dr. Siegwart's research focuses on developing advanced lipid and polymer-based systems with precise control over structure and responsiveness for applications in drug delivery, imaging, genetic diseases, and cancer. His work spans nano-based drugs, personalized medicine, and cancer immunology, with particular emphasis on creating targeted delivery systems for nucleic acid therapeutics. His laboratory pioneers innovations in lipid nanoparticle technology, selective organ targeting (SORT) systems, and novel approaches to overcome delivery barriers for genetic medicines. Analysis of Dr. Siegwart's recent publications reveals a strong focus on advancing lipid nanoparticle technology for organ-specific delivery of nucleic acids. His research group has made significant contributions to understanding structure-activity relationships of ionizable lipids, developing multi-organ targeting strategies, and creating solutions for repeated administration of mRNA therapeutics. Current work emphasizes expanding delivery capabilities beyond the liver to target lungs, spleen, skeletal muscle, and skin for treating genetic diseases and cancer. National Academy of Inventors (NAI) Fellow (2024) National Academy of Medicine (NAM) Emerging Leaders in Health and Medicine (ELHM) Scholar (2024) Controlled Release Society (CRS) College of Fellows (2023) American Institute for Medical and Biological Engineering (AIMBE) College of Fellows (2022) Howard Hughes Medical Institute (HHMI) Gilliam Fellowship for Advanced Study (2021) Dr. Siegwart has secured significant research funding including the American Cancer Society Research Scholar award, CPRIT Scholar Award, and NIH funding. He has co-founded multiple biotechnology companies including Signify Bio, Jumble Therapeutics, and ReCode Therapeutics, translating his academic research into clinical applications. His laboratory maintains active collaborations with leading institutions and pharmaceutical companies to advance nucleic acid delivery technologies. The Siegwart laboratory operates as a multidisciplinary research team at the intersection of chemistry, materials science, and biomedical engineering. The group maintains state-of-the-art facilities for nanoparticle formulation, characterization, and in vivo testing, with particular expertise in lipid chemistry, polymer synthesis, and nucleic acid delivery. Current research directions include developing next-generation delivery systems for CRISPR-based gene editing, creating tissue-specific mRNA vaccines, and engineering novel approaches to treat genetic disorders and cancer.